CLINICAL STUDY

Course of placental 11β-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase mRNA expression during human gestation

Ellen Schoof, Michaela Girstl, Wolfgang Frobenius, Michael Kirschbaum, Reinald Repp, Ina Knerr, Wolfgang Rascher and Jörg Dötsch

Departments of Pediatrics, Obstetrics and Gynecology, University of Erlangen-Nuremberg and Department of Obstetrics and Gynecology, University of Giessen, Germany

(Correspondence should be addressed to Jörg Dötsch, Klinik für Kinder und Jugendliche, Friedrich-Alexander-Universität Erlangen-Nürnberg, Loschgestrasse 15, 91054 Erlangen, Germany; Email: JoergWDoetsch@yahoo.com)

Abstract

Background: During human pregnancy, 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) plays an important role in protecting the fetus from high maternal glucocorticoid concentrations by converting cortisol to inactive cortisone. Furthermore, 11β-HSD2 is indirectly involved in the regulation of the prostaglandin inactivating enzyme 15-hydroxyprostaglandin dehydrogenase (PGDH), because cortisol reduces the gene expression and enzyme activity of PGDH in human placental cells.

Objective: To examine developmental changes in placental 11β-HSD2 and PGDH gene expression during the 2nd and 3rd trimesters of human pregnancies.

Methods: In placental tissue taken from 20 healthy women with normal pregnancy and 20 placentas of 17 mothers giving birth to premature babies, 11β-HSD2 and PGDH mRNA expression was determined using quantitative real-time PCR.

Results: Placental mRNA expression of 11β-HSD2 and PGDH increased significantly with gestational age (r = 0.55, P = 0.0002 and r = 0.42, P = 0.007). In addition, there was a significant correlation between the two enzymes (r = 0.58, P < 0.0001).

Conclusions: In the course of pregnancy there is an increase in 11β-HSD2 and PGDH mRNA expression in human placental tissue. This adaptation of 11β-HSD2 prevents increasing maternal cortisol concentrations from transplacental passage and is exerted at the gene level. 11β-HSD2 up-regulation may also lead to an increase in PGDH mRNA concentrations that, until term, possibly delays myometrial contractions induced by prostaglandins.

European Journal of Endocrinology 145 187–192

Introduction

There are two isoforms of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD), interconverting cortisol and cortisone. In the human fetoplacental unit, the type 1 NADP⁺-dependent form is predominantly found in fetal membranes and acts primarily as an 11-oxoreductase (formation of cortisol from cortisone) (1). Conversion of cortisol to cortisone is achieved by the type 2 NAD⁺-dependent form (11β-HSD2), which is the major form expressed in the syncytiotrophoblast of the placenta from the first trimester onward (1–4). Biochemical studies suggest that the two 11β-HSD enzymes contribute to the metabolism of maternal cortisol and the regulation of fetal cortisol and cortisone concentrations (5, 6). In the baboon, both enzymes have been shown to have important roles in regulating the timely activation of the fetal hypothalamic-pituitary-adrenocortical axis in addition to the maturation of the fetal adrenal gland (7).

During human pregnancy, maternal bound and free cortisol concentrations increase (8–10). To protect the fetus from increased concentrations of maternal cortisol, enzyme activity of placental 11β-HSD2 increases, forming a metabolic barrier. So far, a maturation of this enzyme activity during mid and late gestation has been shown in placental tissue of baboons, pigs and humans (11–13). In humans, placental tissue at term revealed greater 11β-HSD2 enzyme activity than samples from 8–12 and 13–20 weeks (13). Another study with a small number of samples could not detect any difference in placental 11β-HSD2 immunoreactivity or mRNA expression measured by northern blot expression during gestation.
However, no studies on 11β-HSD2 to quantify gene expression during pregnancy in humans have yet been performed.

In a dose-dependent manner, cortisol decreases 15-hydroxyprostaglandin dehydrogenase (PGDH) activity and mRNA expression in placental and chorion trophoblast cells (15). The enzyme inactivates prostaglandin E2 (PGE2) and PGF2α by formation of 15-keto-prostaglandins in placenta and chorion. It is localized primarily in chorionic trophoblasts, but also in the syncytiotrophoblast and the intermediate trophoblast of the placenta (16). For most of the duration of pregnancy, PGDH minimizes myometrial contractility, keeping prostaglandins synthesized by amnion or chorion from reaching decidua and myometrium (16). During early gestation, PGDH activity has been shown to increase (17).

PGDH activity and gene expression have been extensively studied at term and in premature deliveries. In chorion, but not in the placenta, of women going into spontaneous labour at term, levels of PGDH mRNA and activity have been shown to decrease (18). However, studies examining placental PGDH gene expression during human pregnancy are lacking.

The objective of our study was to measure and relate 11β-HSD2 and PGDH gene expression during mid and late gestation in human placenta, using quantitative real-time PCR.

Materials and methods

Patients

The tissue for the study was collected in collaboration with the Departments of Obstetrics and Gynecology at the Universities of Erlangen-Nuremberg and Giessen. Informed consent was obtained from the patients. We obtained the tissue from three different parts of the placenta after removal of amniotic membrane and maternal decidua immediately post partum by vaginal delivery or caesarean section. The tissue originated from 20 healthy women with normal pregnancies (age 21–36 years; 11 at weeks 36–39 of gestation and nine at weeks 40–42 of gestation; 13 spontaneous vaginal deliveries, four primary, and three secondary caesarean sections) and from 20 placentas from 17 premature deliveries (mothers’ age 15–41 years). In the premature group, nine pregnancies terminated between the 18th and 27th weeks of gestation (five spontaneous vaginal deliveries, two primary and two secondary caesarean sections) and 11 between the 30th and 34th weeks of gestation respectively). The study was approved by the ethics committee of the Medical Faculty. Table 1 shows the patients’ characteristics.

RNA extraction and reverse transcription

Total RNA was extracted from the tissues using guanidine–thiocyanate acid phenol (RNAzol, WAK Chemie, Medical GmbH, Bad Homburg, Germany). In view of the fact that placenta has a heterogenous nature, RNA was extracted twice from two separate parts from 13 premature and 18 term placentas. RNA concentrations were determined spectrophotometrically. One microgram of RNA was reversely transcribed in a volume of 20 μl at 39 °C for 60 min (chemicals from Boehringer Mannheim, Mannheim, Germany).

TaqMan real-time PCR

The method has been validated in our laboratory and successfully used for measurements of gene expression in placental tissue previously (19). This novel approach is based upon the 5′ exonuclease activity of the Taq polymerase. Briefly, within the amplicon defined by a gene-specific oligonucleotide primer pair, an oligonucleotide probe labelled with two fluorescent dyes is designed. As long as the probe is intact, the emission of a reporter dye (6-carboxy-fluorescein) at the 5′ end is quenched by the second fluorescence dye (6-carboxytetramethyl-rhodamine) at the 3′ end. During the extension phase of the PCR, the Taq polymerase cleaves the probe, releasing the reporter dye. An automated photometric detector combined with a special software (ABI Prism 7700 Sequence Detection System, Perkin-Elmer, Foster City, CA, USA) monitors the increasing reporter dye emission. The algorithm normalizes the signal to an internal reference (ΔRn) and calculates the threshold cycle number (C_T), when ΔRn reaches 10 times the standard deviation of the baseline. The C_T values of the probes are interpolated to an external reference curve constructed by plotting the relative or absolute amounts of a serial dilution of a known template against the corresponding C_T values.

Commercial reagents (TaqMan PCR Reagent Kit, Perkin-Elmer, Weiterstadt, Germany) and conditions were in accordance with the manufacturer’s procedure. To 25 μl reaction mix were added 2.5 μl cDNA (reverse transcription mixture) and oligonucleotides

Table 1 Characteristics of patients from whom placental tissue was obtained. Values are shown as means±S.E.M.

<table>
<thead>
<tr>
<th>Term group</th>
<th>Preterm group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>29.6±1.0</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>39.0±0.4</td>
</tr>
<tr>
<td>Placental weight (g)</td>
<td>594±30</td>
</tr>
<tr>
<td>Newborns’ weight (g)</td>
<td>3186±121</td>
</tr>
</tbody>
</table>

***P < 0.0001, significant difference from term group. NS, not significant.
with a final concentration of 300 nmol/l primers and 200 nmol/l TaqMan hybridization probe. The oligonucleotides of each target of interest were designed using the Primer Express software (Perkin-Elmer), using uniform selection parameters that allowed the application of the same cycle conditions confirmed by primer optimization. All the primers and probes were purchased from Perkin-Elmer Applied Biosystems (Wildertstadt, Germany) and Eurogentec (Seraing, Belgium). The thermocycler parameters were 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Serial dilutions of one of the samples served as reference, providing relative quantification of the unknown samples.

11β-HSD2 and PGDH gene expression was related to the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-actin, and porphobilinogen deaminase (PBGD). In former studies, PBGD has proved suitable as housekeeping gene (20, 21); its sequence does not co-amplify pseudogenes. Table 2 shows the primers and TaqMan probes used.

### Statistical analysis

All values are expressed as means±s.e.m. After being tested for Gaussian distribution, parametric data were compared using Student’s t-test. Data of mRNA expression were interrelated and related to birth weight and placental weight using linear regression for parametric data. A P value less than 0.05 was considered significant.

### Results

With the passage of gestational age, a significant increase in placental 11β-HSD2/PBGD mRNA expression (r = 0.55, P = 0.0002; Fig. 1a) could be observed. Normalization of 11β-HSD2 to β-actin and GAPDH revealed similar results (r = 0.53, P = 0.0004 and r = 0.56, P = 0.0002 respectively). 11β-HSD2/PBGD gene expression was significantly greater in placental tissue obtained at term than from patients who delivered prematurely (10.3 ± 1.18 relative units (RU) and 3.15 ± 0.93 RU, P < 0.0001) (Fig. 2a). Again, normalization to β-actin and GAPDH confirmed the results (P = 0.0002 and P = 0.0001 respectively). Significant correlations of placental 11β-HSD2/PBGD mRNA expression were seen to birth weight (r = 0.57, P = 0.0004; 11β-HSD2/β-actin: r = 0.59, P = 0.0002; 11β-HSD2/GAPDH: r = 0.63, P < 0.0001) and to placental weight (r = 0.57, P = 0.0008; 11β-HSD2/β-actin: r = 0.60, P = 0.0004; 11β-HSD2/PBGD: r = 0.62, P = 0.0002).

As for 11β-HSD2, there was an increase in gestational age-related PGDH/PBGD mRNA expression (r = 0.42, P = 0.007; Fig. 1b). Normalization of PGDH to β-actin (r = 0.44, P = 0.005) and GAPDH (r = 0.51, P = 0.0009) showed similar results. The gene expression of PGDH/PBGD was significantly greater in placenates of patients giving birth to term babies than in those delivering premature neonates (9.07 ± 1.09 RU and 4.63 ± 0.83 RU, P = 0.002) (Fig. 2b). Relation to β-actin and GAPDH also revealed significant results (P = 0.02 and P = 0.01 respectively). A significant correlation of placental PGDH/PBGD mRNA expression to birth weight was found (r = 0.38, P = 0.03; PGDH/β-actin: r = 0.35, P = 0.04; PGDH/GAPDH: r = 0.43, P = 0.01). However, there was no significant correlation between placental weight and PGDH gene expression (P > 0.05) for all the housekeeping genes.

Finally, a significant correlation was found in respect to the gene expressions of the two enzymes 11β-HSD2/PGDH and PGDH/PBGD (r = 0.58, P < 0.0001, Fig.

---

**Table 2 Primers and TaqMan probes.**

<table>
<thead>
<tr>
<th>GAPDH</th>
<th>Forward 5′-CCCACTTGGTCTATGCGG-3′</th>
<th>Reverse 5′-TGAGATGATGGTCTCTCCACAGATA-3′</th>
<th>TaqMan probe 5′ (FAM)-CTGCACCAACTGCTGTAGGACCC-(TAMRA) 3′</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>Forward 5′-CCGAGAAAGATGCCAACGGAT-3′</td>
<td>Reverse 5′-CCAGTGATGAGCCAGGAGG-3′</td>
<td>TaqMan probe 5′ (FAM)-CCAGCATGTAAGTTGCTTCCACAGGC-(TAMRA) 3′</td>
</tr>
<tr>
<td>PBGD</td>
<td>Forward 5′-TGTGTCGCAAGATCCCG-3′</td>
<td>Reverse 5′-ACACTGCAAGCTCCTCCAG-3′</td>
<td>TaqMan probe 5′ (FAM)-CTTGGCTGCAAGCTCCTCCAG-3′</td>
</tr>
<tr>
<td>11β-HSD</td>
<td>Forward 5′-CCGTTAGGAGTTGAAACGCG-3′</td>
<td>Reverse 5′-CAACTAATCTTGTGCGCTGC-3′</td>
<td>TaqMan probe 5′ (FAM)-CTAGAGTTCAAGCCACGCCACAGCC-(TAMRA) 3′</td>
</tr>
<tr>
<td>PGDH</td>
<td>Forward 5′-AAGCAAAATGGAGGTGGAAGGC-3′</td>
<td>Reverse 5′-TGGCATCTCAGTCTCAACACAC-3′</td>
<td>TaqMan probe 5′ (FAM)-CATCCTTACAGGATCAGTGGCGCTTGC-(TAMRA) 3′</td>
</tr>
</tbody>
</table>

FAM, 6-carboxy-fluorescein; TAMRA, 6-carboxy-tetramethyl-rhodamine.
1c). Similar results were achieved when normalizing to the housekeeping genes $\beta$-actin ($r = 0.33, P = 0.03$) and GAPDH ($r = 0.36, P = 0.02$).

The mode of birth – spontaneous vaginal delivery or caesarean section – did not influence either $11\beta$-HSD2 or PGDH gene expression ($P > 0.05$) in the placental tissues.

To confirm the results, RNA was extracted from a different part in 31 placentas and the genes $11\beta$-HSD2, PGDH and PBGD were quantified twice. Again, a correlation to gestational age was found ($11\beta$-HSD2/PGDH: $r = 0.47, P = 0.0007$; PGDH/PBGD: $r = 0.43, P = 0.01$). Gene expression in term placentas was confirmed to be significantly greater than in premature placentas ($11\beta$-HSD2/PBGD: $P = 0.0004$; PGDH/PBGD: $P = 0.02$) in addition to the correlation between $11\beta$-HSD2 and PGDH mRNA expression.

Figure 1 Significant increase in (a) $11\beta$-HSD2/PBGD ($r = 0.55, P = 0.0002$) and (b) PGDH/PBGD ($r = 0.42, P = 0.0007$) mRNA expression in placental tissue with advancing gestation. (c) Correlation between the gene expression of $11\beta$-HSD2/PBGD and PGDH/PBGD in placentas of premature and term deliveries ($r = 0.58, P < 0.0001$).

Figure 2 Significant increase in (a) $11\beta$-HSD2/PBGD ($P < 0.0001$) and (b) PGDH/PBGD ($P = 0.002$) mRNA expression in placental tissue from term deliveries compared with premature deliveries (Preterm).
This interrelation is further strengthened by our finding however, could only be demonstrated for 11β-HSD2/PGDH (r = 0.67, P = 0.0003).

**Discussion**

In the course of pregnancy there is a significant increase in the gene expression of the cortisol and prostaglandin metabolizing enzymes 11β-HSD2 and PGDH in human placental tissue. As far as we know, this was demonstrated for the first time in the present study. Our results are supported by some theories and findings of other investigators. We were able to provide evidence that the previously described increase in placental 11β-HSD2 enzyme activity during human pregnancy is based on increased gene expression (13).

According to former in vitro work, 11β-HSD2 is regulated by oestrogens in a paracrine manner (22). In the placenta, oestrogens are synthesized predominantly from androgen precursors produced by the fetal adrenal. Therefore, increasing quantities of these androgens cause placental oestrogen concentrations to increase in the course of pregnancy. Consecutively, this seems to up-regulate 11β-HSD2 gene expression. This interrelation is further strengthened by our finding that 11β-HSD2 gene expression correlates significantly with birth weight and placental weight. The mode of delivery had no influence on placental 11β-HSD2 mRNA expression. These data are in line with a previous study showing unchanged 11β-HSD2 mRNA levels in chorion and placenta as measured by northern blot after different modes of labour (1).

As mentioned, studies in baboons have led to the hypothesis that increasing 11β-HSD2 enzyme activity is not only protecting the fetus from high maternal cortisol concentrations, but also supporting the maturation of the fetal adrenal (7). When pregnancy progresses, 11β-HSD2 builds a transplacental barrier, preventing cortisol from reaching the fetus. The resulting lower serum cortisol concentrations are believed to stimulate the activation of the fetal hypothalamo–pituitary–adrenocortical axis. As a consequence, the definitive zone of the adrenal grows to achieve adequate adrenocortical function. Our results support the notion that the regulation of 11β-HSD2 and fetal adrenal development is taking place in humans in a similar way as in primates.

Glucocorticoids inhibit PGDH enzyme activity in cultured human placental syncytiotrophoblast and chorion trophoblast cells (15). PGDH mRNA expression is increased by progesterone (23). The inhibitory effect of cortisol on PGDH activity seems to be mediated by the mineralocorticoid receptor, as has been demonstrated recently (15, 24). We found a positive correlation between 11β-HSD2 and PGDH mRNA expression. In our opinion, this supports the hypothesis that increased oxidation of cortisol to inactive cortisone could only be demonstrated for 11β-HSD2/PGDH (r = 0.67, P = 0.0003).

The increasing placental expression of the two important cortisol and prostaglandin metabolizing enzymes, 11β-HSD2 and PGDH, during human gestation can be expected to generate low levels of active glucocorticoids and prostaglandins at the maternal–fetal interface, promoting fetal maturation and uterine quiescence in late gestation. However, as labour is associated with increased concentrations of cortisol in maternal and fetal serum and amniotic fluid, this suggests that parturition is associated with enhanced cortisol and prostaglandin action at the uterine-placental interface. Furthermore, a positive correlation suggests an interaction of both enzymes.

**Acknowledgements**

We thank Ulla Jacobs and Ida Allabauer for their helpful assistance.

**References**


Received 19 December 2000
Accepted 26 April 2001